Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies

    The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodi…

    FromVJHemOnc Podcast

    Start listeningView podcast show

    The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodi…

    FromVJHemOnc Podcast

    ratings:
    Length:
    13 minutes
    Released:
    May 16, 2024
    Format:
    Podcast episode

    Description

    Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR...
    The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.
    Released:
    May 16, 2024
    Format:
    Podcast episode

    Titles in the series (100)

    The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com